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Abstract
Background/Objective: Novel biomarkers identifying and predicting disease activity in multiple scle-
rosis (MS) would be valuable for primary diagnosis and as outcome measures for monitoring therapeutic
effects in clinical trials. Axonal loss is present from the earliest stages of MS and correlates with
disability measures. Growth-associated protein 43 (GAP-43) is a presynaptic protein with induced
expression during axonal growth. We hypothesized this protein could serve as a biomarker of axonal
regeneration capacity in MS.
Methods: We developed a novel GAP-43 enzyme-linked immunosorbent assay for quantification in
cerebrospinal fluid (CSF) and measured GAP-43 levels in 71 patients with clinically isolated syndrome,
139 MS patients and 51 controls.
Results: GAP-43 concentrations were similar in patients and controls. Nevertheless, GAP-43 levels
were higher in patients with >10 T2-magnetic resonance imaging (MRI) lesions (p¼ 0.005). CSF GAP-
43 concentrations correlated with CSF mononuclear cell counts (p¼ 0.031) and were inversely corre-
lated with patient age (p¼ 0.038) with a trend for higher CSF GAP-43 concentrations in patients with
gadolinium-enhancing MRI lesions and positive CSF oligoclonal immunoglobulin G status.
Conclusion: Our results suggest that axonal regeneration capacity is relatively preserved in early MS.
CSF GAP-43 concentration is positively associated with markers of inflammation, suggesting possible
inflammatory-driven expression of this growth-associated protein in early MS.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory
and degenerative disease of the central nervous
system (CNS) that affects young people and is a
major cause of disability in this age group. MS usu-
ally starts with relapses and remissions and progres-
sion occurs later, while clinically isolated syndrome
(CIS) refers to the first attack of the disease.1 Many
immunomodulatory agents that reduce the relapse
rate and disability progression are available for MS
and often are also prescribed to patients with CIS.1
Because most disease-modifying drugs for MS have
safety and tolerability issues (for example, increased
risk for progressive multifocal leukoencephalopathy
in patients treated with natalizumab), treatment
decisions are sometimes difficult. Biomarkers that
could predict disease course and response to treat-
ment are needed and would help in the clinical man-
agement of MS patients.
Different neuronal and glial proteins in cerebrospi-
nal fluid (CSF) have been investigated for their diag-
nostic and prognostic potential in MS.2 Axonal loss,
which is present from the earliest stages of the dis-
ease, correlates importantly with clinical disability
and is crucial for disease progression.3,4
Correspondingly, increased concentration of neuro-
filament light chains (NFLs) released into the CSF
following axonal damage was shown to predict
relapses, disability progression and development of
gadolinium (Gd)-enhancing lesions. 2,4,5
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Complete recovery observed during early remissions
is mainly due to remyelination and resolution of
inflammation.1 However, some studies indicate that
compensation of axonal damage may also occur in
MS.6,7 Axonal remodeling and concurrent expres-
sion of growth-associated protein 43 (GAP-43)
were demonstrated in an animal model of MS.7
GAP-43 is a known marker of growth cones, synap-
tic plasticity and synaptic and axonal regeneration.8
It was shown to drive spontaneous sprouting of
axons in transgenic mouse lines overexpressing
GAP-43.9 GAP-43 synthesis was demonstrated in
developing neurons and was upregulated after axot-
omy simultaneously with or prior to initiation of
axonal outgrowth.8,10 Alongside traumatic injury
inflammatory lesions may as well induce changes
in axonal connectivity with parallel expression of
GAP-43.7 In the post mortem MS brain increased
levels of GAP-43 were observed in remyelinated
white matter, which possibly reflects regeneration
attempts of the damaged axons.6 In the same study
CSF GAP-43 concentrations were negatively corre-
lated with magnetic resonance imaging (MRI) meas-
ures of atrophy, indicating lower numbers of axons
in the brain.6 Furthermore, lower CSF GAP-43
levels were found in patients with secondary pro-
gressive MS compared with relapsing–remitting
MS (RRMS), implying lost or reduced regenerating
capacity of axons in late MS.11
We measured CSF GAP-43 concentration in a large
number of CIS and early RRMS patients as well as
in control individuals to test whether CSF GAP-43
concentration could serve as an axonal regeneration
marker in MS. Most CIS and MS patients were clin-
ically assessed by Expanded Disability Status Scale
(EDSS) score, CSF and MRI analysis, enabling us to
study possible associations between GAP-43 con-
centration and disease activity and severity. If
axonal regeneration capacity, as evidenced by CSF
GAP-43, is preserved in early MS, similar concen-
trations in patients and control individuals (or even
higher in patients) would be observed. Thus, mea-
surement of CSF GAP-43 could possibly be used as
a biomarker for axonal regeneration potential in an
individual with MS.
Materials and methods
Patient selection
A total of 210 patients, 71 with CIS (49 (69%)
women), and 139 with MS (92 (66%) women) and
51 control individuals (30 (59%) women) were
included in the study. Among MS patients 118 had
RRMS, 19 primary progressive MS and two second-
ary progressive MS. The diagnosis of MS was estab-
lished according to the McDonald criteria, and
hospital charts of CIS and MS patients from the
Department of Neurology, University Medical
Centre, Ljubljana, were reviewed for clinical and
paraclinical data at the time of lumbar puncture.
Outpatient charts were also reviewed for clinical
data at one-year follow-up (EDSS increase of 0.5
points, relapses, disease-modifying treatments). The
control group included patients with degenerative
spine diseases, primary headaches and psychiatric
symptoms. The study was approved by the
Republic of Slovenia National Medical Ethics
Committee (number 0120-150/2017-3). All partici-
pants provided written informed consent for lumbar
puncture and permitted future research with the
remaining samples.
Routine CSF analysis
CSF samples were also collected at the Department
of Neurology, University Medical Centre, Ljubljana,
from 2013 to 2016 for routine diagnostic procedures
in all patients and controls. The remaining CSF was
centrifuged and afterward stored at 80C. Total
CSF protein, albumin, and immunoglobulin (Ig)G
and IgM levels were determined with nephelometry
(Siemens BN ProSpec). Oligoclonal IgG bands
(OBs) were detected by isoelectric focusing and
immunoblot with alkaline phosphatase-labeled anti-
human IgG.
GAP-43 determination
Nunc-Immuno Polysorp microwell modules
(Thermo Fisher Scientific, MA, USA) were coated
with mouse anti-GAP-43 antibody (0.77 mg/ml NM4,
Fujirebio, Tokyo, Japan) in carbonate buffer pH 9.6,
overnight at 4C. After washing, wells were blocked
with phosphate-buffered saline (PBS)/0.05%Tween/
1x Casein (10x Casein blocking buffer, B6429,
Sigma-Aldrich, MO, USA) for one hour at room
temperature. Thereafter, full-length, in-house recom-
binant GAP-43 calibrators (78 pg/ml–5000 pg/ml),
blanks, prediluted control samples and CSF samples
in assay diluent (1%BSA/PBS/0.05%Tween) were
coincubated with a rabbit anti GAP-43 detector anti-
body (0.14 lg/ml Cat. no: ABB-135, produced
through immunization with aa216-238 of GAP-43,
Nordic Biosite, T€aby, Sweden) overnight at 4C.
After additional washes, plates were incubated
with anti-rabbit horseradish peroxidase (1:30,000,
Promega, WI, USA) for 1.5 hours. After subsequent
washes, wells were incubated for 20 minutes with
3,3,5,5-tetramethylbenzidine (TMB, KemEnTech
Diagnostics, Taastrup, Denmark) in the dark.
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The color reaction was stopped by addition of 0.2 M
H2SO4 and the absorbance was read in a Sunrise
TM
microplate absorbance reader (Tecan group,
M€annedorf, Switzerland) at 450 nm (650 nm as ref-
erence value). CSF sample concentration was calcu-
lated via interpolation from the calibrator curve
(four-parameter logistic fit weighted 1/Y2).
In-house GAP-43 enzyme-linked immunosorbent
assay (ELISA) characterization
The performance of the novel ELISA was evaluated
in leftover CSF samples from clinical routine. The
assay precision was determined by measuring the
GAP-43 concentration in two CSF pools, aliquoted
and stored at 80C, in five to seven duplicates on
three different occasions. The lower limit of quanti-
fication was calculated as the mean of 16 blank
duplicates plus 10 times its standard deviation.
Sample dilution linearity was measured by dilution
of three CSF samples with endogenously high
GAP-43 levels and diluting 1:1–1:4. Recovery was
evaluated by dividing two CSF samples in four ali-
quots and spiking with 0, 500, 750 or 1000 pg/ml
calibrator before analysis. As GAP-43 shares a pro-
tein domain with neurogranin,12 specificity of the
assay was assessed by spiking full-length, in-house
recombinant neurogranin at 1000–50,000 pg/ml into
aliquots of two CSF samples that were analyzed
simultaneously with a neat aliquot. Sample stability
was evaluated by dividing six samples into nine ali-
quots, where one was directly placed at 80C, and
the others stored at –20C or at 4C overnight or for
one week, at room temperature for 24 hours, or
freeze-thawed one to four times.
NFL immunoassay
CSF NFL quantification was performed in a sub-
group of CIS/MS patients using Uman Diagnostics
NF-lightV
R
ELISA according to the manufacturer’s
instructions. The assay is based on anti-NFL mono-
clonal antibodies and has a detection limit of 32 pg/
ml. Intraassay coefficient of variation (CV) was
<5% and an internal control sample was used to
check the validity of results.
Statistics
Statistical analysis was performed with GraphPad
Prism, version 6 (GraphPad Software, San Diego,
CA, USA). Fisher, Mann–Whitney U and Kruskal–
Wallis tests were used as appropriate for comparison
of the data, and Spearman coefficient was calculated
for correlation analyses.
Results
Demographic and clinical characteristics
Patients with CIS and MS were slightly younger than
controls (p¼ 0.030) with a median age of 36 years
(range, 21–55), 38 years (range, 15–70) and 46 years
(range, 15–72) in the CIS, MS and control groups,
respectively. Median duration of the disease was 0
years (range, 0–3) in CIS and one year (range, 0.5–
25) in MS patients. Median EDSS score in patients
was 2 (range, 0–7), in patients with CIS 1.25 (range,
0–3.5) and in patients with MS 2 (range, 0–7).
Out of 210 patients, 33 were lost to follow-up and 88
patients (as expected in a real-life setting) started
with disease-modifying treatment. From 89
untreated patients (47 MS and 42 CIS patients), 13
(15%, 11 with MS and two with CIS) developed
disability progression (>0.5 points on EDSS score)
and 16 (18%, seven with MS and nine with CIS) had
one or more relapses. None of the patients had both
relapses and disability progression.
In-house GAP-43 ELISA characterization
The repeatability and interassay precision of a CSF
pool with a concentration of 2992 pg/ml was 7.3%
CV and 7.8% CV respectively, and for a CSF pool
of 719 pg/ml, the repeatability was 9.8% CV and the
interassay precision was 13.7% CV. The lower limit
of quantification was 156 pg/ml and sample dilution
linearity was 95% on average. Recovery of calibra-
tor standard was 106% on average. Both dilution
linearity and recovery were within recommended
levels according to Andreasson et al.13 Spiking in
recombinant neurogranin (1–50 ng/ml) did not
affect the GAP-43 concentration (11% CV, recovery
of neurogranin –3% to 0%). CSF GAP-43 measure-
ments were stable after one to four freeze-thaw
cycles (n¼ 9; 100.9%–107.9%) and various storage
temperatures (n¼ 7; 94.8%–103.5%, percentage of
80C stored aliquot concentration).
GAP-43 and main CSF characteristics
Similar CSF GAP-43 levels were observed in con-
trols and patients (p¼ 0.516). Median concentrations
were 1701 pg/ml (range, 318–2987), 1497 pg/ml
(range, 183–4573) and 1622 pg/ml (range, 426–
7108) in the control, CIS and MS groups, respective-
ly (Figure 1). There was no correlation between
GAP-43 and CSF/serum albumin ratio (p¼ 0.3551).
CSF mononuclear white cell counts were elevated in
34 out of 70 (49%) CIS patients and in 58 out of 135
(43%) MS patients. Median GAP-43 concentrations
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were 1649 pg/ml (range, 453–5011) in patients
with elevated CSF cell counts compared with 1516
pg/ml (range, 182–7108) in patients with normal
CSF cell counts; p¼ 0.1310. A weak but statistically
significant correlation of CSF GAP-43 concentration
with CSF mononuclear cell count was found
(r¼0.150, p¼ 0.031; Figure 2). OBs were
detected in 77% (55/71) of CIS patients and 94%
(128/136) of MS patients. Median GAP-43 levels
trended higher in OB-positive than in OB-negative
patients; 1598 pg/ml (range, 293–7108) compared
with 1380 pg/ml (range, 1832–3262); p¼ 0.080.
Intrathecal IgM synthesis was present in 12/67
(18%) CIS and 32/131 (24%) MS patients.
Median GAP-43 concentration did not differ
between IgM-negative (1638 pg/ml; range, 182–
7108) and IgM-positive patients (1504 pg/ml;
range, 453–4573, p¼ 0.7918).
Figure 1. CSF GAP-43 in patients and control individuals.
CIS: clinically isolated syndrome; CSF: cerebrospinal fluid; GAP-43: growth-associated protein 43; MS: multiple
sclerosis; NIND: noninflammatory neurological disease.
Figure 2. GAP-43 concentrations are in correlation with CSF MNC.
CSF: cerebrospinal fluid; GAP-43: growth-associated protein 43; MNC: mononuclear cell counts.
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GAP-43 and MRI lesions
A high number of T2 lesions (>10) were present in
24/66 (36%) CIS patients and in 94/136 (70%) MS
patients. Significantly higher CSF GAP-43 concen-
tration was observed in patients with >10 T2 lesions
(median 1788 pg/ml, range, 426–7108) compared
with patients with lower numbers of T2 lesions
(median 1310 pg/ml, range, 495–6447; p¼ 0.005,
Figure 3). Nevertheless, when patients with high
numbers of T2 lesions were further divided into an
MS and CIS group, the difference was significant
only for MS patients (p¼ 0.026). Forty-three percent
of all CIS and MS patients (77/181) had Gd-
enhancing lesions, while spinal cord lesions were
present in 20/24 (83%) CIS patients and 58/65
(89%) MS patients. There was a trend for higher
GAP-43 concentrations in patients with Gd-
enhancing lesions (median 1727 pg/ml, range, 426–
5906) compared with patients without Gd-enhancing
lesions (1504 pg/ml, range, 293–7108; p¼ 0.2002).
Median CSF GAP-43 levels did not differ signifi-
cantly between patients with or without spinal cord
lesions (p¼ 0.588).
GAP-43 and clinical features
Overall there was no correlation between GAP-43
concentrations and age (r¼0.078; p¼ 0.2106),
but a weak negative correlation between GAP-43
levels and age was found in patients (rs¼0,145;
p¼ 0.038), which was not seen in controls
(rs¼ 0.145; p¼ 0.312). GAP-43 concentrations
were not associated with gender (p¼ 0.745). There
was no correlation between GAP-43 and disability
according to EDSS score (rs¼0.101; p¼ 0.150)
and no association with disease duration
(p¼ 0.909). Prolonged latencies of visual evoked
potentials (VEP) were found in 4/13 (31%) CIS
and 27/40 (67%) MS patients, but median GAP-43
concentrations were not significantly different
among patients with prolonged and normal VEP
(p¼ 0.499). Patients who progressed had lower
median GAP-43 concentrations, 1033 pg/ml (range,
495–2715) than patients without progression,
1555 pg/ml (range, 293–6447); p¼ 0.0269. Median
GAP-43 concentrations trended higher in patients
with relapses, 1897 pg/ml (range, 691.5–4573) com-
pared with patients without relapses at one year,
1446 pg/ml (range, 293–6447); p¼ 0.1059.
GAP-43 and NFL. In addition to GAP-43, CSF NFL
were measured in 85 MS and CIS patients with one-
year follow-up data. Median NFL concentrations
were 552 pg/ml (range, 46–3200). There was a
trend for patients with CIS to have lower concentra-
tions of NFL, 494.7 pg/ml (range, 46.3–3200) than
patients with MS, 582.9 pg/ml (range, 154.2–2060);
p¼ 0.1405. Median CSF NFL concentrations were
similar in patients with relapses, 468 pg/ml (range,
46–1784) and in patients without relapses, 566 pg/ml
(range, 76–3200); p¼ 0.5112 in the first year. There
was also no difference between patients with pro-
gression in the first year, whose median NFL were
557 pg/ml (range, 360–2360), and patients without
progression, whose median NFL were 548 pg/ml
(range, 46–3200); p¼ 0.1916. Moreover, no correla-
tion between GAP-43 and NFL concentrations was
observed (r¼ 0.090; p¼ 0.4050) in this subgroup
of patients.
Figure 3. GAP-43 and T2-brain MRI lesions.
CSF: cerebrospinal fluid; GAP-43: growth-associated protein 43; MRI: magnetic resonance imaging.
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Discussion
CSF GAP-43 concentrations in our CIS and RRMS
patients were not different compared with control
individuals without neurodegeneration and CNS
inflammation. This suggests that axonal regeneration
capacity is relatively preserved in early MS.
Our findings are in contrast with the results of
Gnanapavan et al., who found low GAP-43 concen-
trations in different stages of MS in comparison with
controls.14 Gnanapavan et al. used NM2 as capture
antibody, and another commercial C-terminal GAP-
43 antibody as detector in their in-house ELISA.
NM2 is known to have an epitope spanning an IQ
domain and thereby binding both GAP-43 and neu-
rogranin,12 which is not the case for NM4. In addi-
tion, Gnanapavan and coauthors used a modified
recombinant protein as calibrator. These differences
may explain why our results are not directly compa-
rable. On the other hand, in a study by H€aggmark
et al. in which antibody-based CSF profiling was
used there was a difference between CSF GAP-43
concentrations between secondary progressive and
RRMS patients. Patients with progressive MS had
lower CSF GAP-43 concentrations, indicating lost
or reduced regenerative potential in late MS.11 In a
neuropathological study by Teunissen et al., howev-
er, increased GAP-43 expression in remyelinated or
nondemyelinated white matter in the vicinity of MS
plaques was found and may confirm regenerative
attempts by the damaged axons. The authors also
report a negative correlation between CSF GAP-43
concentrations and brain atrophy measures.6 Another
pathological study showed that neuroaxonal regen-
eration was more pronounced in early MS compared
with traumatic brain injury.15 CSF GAP-43 increases
that may reflect inherent attempts to limit axonal
damage were also observed in primarily neurodegen-
erative diseases.16,17 For example, tissue-specific
changes in GAP-43 expression and higher CSF
GAP-43 concentrations were found in patients with
Alzheimer disease compared with controls.16,17 This
in contrast was not seen in patients with frontotem-
poral dementia.18
In our study, CSF GAP-43 concentrations were sig-
nificantly higher in patients with more than 10
T2-MRI lesions compared with those with a lower
number of T2 lesions. They correlated weakly with
CSF mononuclear cell counts and were inversely
correlated with patient age. There was also a trend
for higher GAP-43 levels in patients with Gd-
enhancing lesions and positive OBs, which could
suggest that more pronounced inflammation in MS
induces more axonal regeneration. Though this
hypothesis might appear speculative, beneficial
effects of inflammation on endogenous repair mech-
anisms in MS and experimental demyelination have
already been reported. For example, it was shown
that inflammation associated with CNS demyelin-
ation provided a stimulus for the activation of oligo-
dendrocyte precursor cells with subsequent
remyelination.19 One could argue that higher levels
of CSF GAP-43 were found in patients with high
numbers of T2 lesions in whom plaques could con-
sist mainly of demyelination, neurodegeneration or
gliosis. But it is also known that in early plaques
(our CIS and MS patients had median disease dura-
tion of 0 or 1.25 years, respectively), inflammation
and demyelination processes are predominant.20
Unfortunately MRI data on brain atrophy were not
available for our patients, thus we were not able to
examine the association between CSF GAP-43 and
brain atrophy.
Our follow-up data are short (one year) and incom-
plete as is expected in a real-life setting. Fifteen
percent of patients were lost to follow-up and more
than 40% of the included patients immediately
started with disease-modifying agents. The number
of patients with relapses or disability progression in
our untreated patients was low. This is not surprising
because patients with higher risk of clinical activity
started disease-modifying treatment at the diagnosis.
The untreated patients who progressed in the first
year had lower GAP-43 levels, which confirms the
role of GAP-43 as an axonal regeneration marker.
On the other hand, GAP-43 concentrations trended
higher in patients with relapses in the first year,
which is in agreement with our cross-sectional find-
ings showing that the expression of GAP-43 could
be inflammatory driven. It would be very interesting
to see whether the effect seen on relapses was also
present on MRI, but unfortunately our control MRI
data were not good enough for inclusion in the study.
CSF NFLs were also measured in a selected group of
patients with follow-up information and trended
lower in CIS compared with MS patients, which is
expected—less axonal loss is present in patients with
the earliest MS. Absence of correlation between
GAP-43 and NFLs does not come as a surprise.
Namely, GAP-43 levels were shown to be at the
same time positively associated with inflammatory
activity of early MS (high brain MRI lesions at the
diagnosis and relapses in first year) but on the other
hand negatively associated with disability progres-
sion. We found no correlation between NFL and
Multiple Sclerosis Journal–Experimental, Translational and Clinical
6 www.sagepub.com/msjetc
clinical activity in MS, which was disappointing.
Absence of correlation could be due to biased selec-
tion of patients—CSF NFLs were determined only in
untreated MS (even more often CIS) patients with
follow-up data who had milder clinical course and
fewer MRI lesions. Furthermore, the duration of
follow-up was too short.
Lumbar puncture with CSF examination is an impor-
tant part of diagnostic workup in patients with sus-
pected MS and was again included in the latest
revisions to the McDonald criteria.21 Besides bio-
markers that support the diagnosis of MS (e.g.
OBs), there is room for biomarkers that could predict
the clinical course in an individual. This is extremely
important because more than 15 drugs with different
efficacy, safety and tolerability profiles are now
available for MS. With the CSF markers of axonal
loss (NFLs) or microglial activation (YKL-40,
TREM-2), one can predict early unstable disease
and late disability in a patient with MS.2,4,22
Perhaps biomarkers for axonal regeneration capaci-
ty, GAP-43 or others, could in the future provide
additional useful information in treatment deci-
sion making.
Some of our MS patients, as seen in Figure 1, had
very high concentrations of GAP-43. Longitudinal
studies should be undertaken to reveal whether
these individuals are better off over time and more
responsive to immunomodulatory treatment.
If remodeled axonal connections are proven to be
sufficient for functional recovery, further research
on GAP-43 and axonal regeneration potential in
MS will also be justified in view of novel therapeutic
strategies.
To conclude, CSF levels of GAP-43 were similar in
patients with CIS, RRMS and controls, indicating
that axonal regeneration potential is preserved in
early MS. We also found that indicators of CNS
inflammation are associated with CSF GAP-43, sug-
gesting that expression of this growth-associated
protein may be inflammatory driven in early MS.
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